TRANZYME
Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies. The company currently has programs for gastrointestinal motility disorders and retains worldwide rights for these programs. The company’s product portfolio includes, TZP-101, for the treatment of post-operative ileus and severe gastroparesis; and TZP-301, for the treatment of obesity and metabolic syndrome. Tranzyme Pharma is based in North Carolina, United States.
TRANZYME
Industry:
Biotechnology Medical Therapeutics
Founded:
1998-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.tranzyme.com
Total Employee:
11+
Status:
Closed
Total Funding:
20 M USD
Current Advisors List
Current Employees Featured
Investors List
H.I.G. Capital
H.I.G. Capital investment in Venture Round - Tranzyme
BDC Venture Capital
BDC Venture Capital investment in Venture Round - Tranzyme
Quaker BioVentures
Quaker BioVentures investment in Venture Round - Tranzyme
Thomas, McNerney & Partners
Thomas, McNerney & Partners investment in Venture Round - Tranzyme
Quaker BioVentures
Quaker BioVentures investment in Series A - Tranzyme
Pacific Rim Ventures
Pacific Rim Ventures investment in Series A - Tranzyme
Desjardins Venture Capital
Desjardins Venture Capital investment in Series A - Tranzyme
H.I.G. Capital
H.I.G. Capital investment in Series A - Tranzyme
Thomas, McNerney & Partners
Thomas, McNerney & Partners investment in Series A - Tranzyme
BDC Venture Capital
BDC Venture Capital investment in Series A - Tranzyme
